Poseida Therapeutics, Inc.

PSTX

US73730P1084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.13 ^USD	+3.90%		+5.45%	-36.61%

Apr. 08	Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma	CI
Mar. 25	Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer	MT

Poseida Therapeutics, Inc. announced that it has received $24.999999 million in funding from Astellas US, LLC

August 06, 2023

On August 07, 2023, Poseida Therapeutics, Inc. closed the transaction. The transaction included participation from a single investor.

Latest news about Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma	Apr. 08	CI
Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer	Mar. 25	MT
Poseida Therapeutics, Inc Appoints Syed Rizvi as Chief Medical Officer Effective April 1, 2024	Mar. 25	CI
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q4 Revenue $25M	Mar. 07	MT
Poseida Therapeutics, Inc. Announces Executive Changes	Mar. 07	CI
Poseida Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Piper Sandler Adjusts Price Target on Poseida Therapeutics to $10 From $8, Maintains Overweight Rating	Dec. 11	MT
Poseida Therapeutics Reports Positive Results of Phase 1 Blood Cancer Treatment Trial	Dec. 11	MT
Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment	Dec. 11	DJ
HC Wainwright Adjusts Price Target on Poseida Therapeutics to $20 From $15, Keeps Buy Rating	Dec. 11	MT
Poseida Therapeutics, Inc. Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology Annual Meeting	Dec. 10	CI
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Posts Q3 Revenue $9.4M	Nov. 09	MT
Poseida Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Poseida Therapeutics, Inc. Announces Board Changes	23-10-10	CI
Poseida Therapeutics, Inc. Announces Chief Executive Officer Changes	23-10-10	CI
Poseida Therapeutics Names Kristin Yarema as CEO, Mark Gergen as Executive Chairman	23-10-09	MT
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q2 Revenue $20M	23-08-08	MT
Poseida Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Poseida Therapeutics Secures $50 Million Strategic Investment From Astellas; Shares Gain	23-08-07	MT
Poseida Therapeutics Shares Leap on Astellas Investments	23-08-07	DJ
Poseida Therapeutics in $50 Million Investment Deal With Astellas	23-08-07	DJ
Poseida Therapeutics, Inc. announced that it has received $24.999999 million in funding from Astellas US, LLC	23-08-06	CI
Poseida Therapeutics, Inc. announced that it expects to receive $24.999999 million in funding from Astellas US, LLC	23-08-03	CI

Chart Poseida Therapeutics, Inc.

Duration

Period

More charts

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. Its pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors, as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. Its approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System, Booster Molecule and nanoparticle and hybrid gene delivery technologies, as well as in-house GMP cell therapy manufacturing. Its lead programs, including P-FVIII-101, a non-viral approach. Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. P-BCMA-ALLO1 is in a Phase I trial, being developed for patients with relapsed/refractory multiple myeloma.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Poseida Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.13 USD

Average target price

14 USD

Spread / Average Target

+557.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
POSEIDA THERAPEUTICS, INC.	-36.61%	206M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs